- Home
- RVPH vs IBIO Comparison
RVPH vs IBIO Comparison
Compare RVPH & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVPH
- IBIO
- Stock Information
- Founded
- RVPH 2006
- IBIO 2008
- Country
- RVPH United States
- IBIO United States
- Employees
- RVPH N/A
- IBIO N/A
- Industry
- RVPH Biotechnology: Pharmaceutical Preparations
- IBIO Biotechnology: Pharmaceutical Preparations
- Sector
- RVPH Health Care
- IBIO Health Care
- Exchange
- RVPH Nasdaq
- IBIO Nasdaq
- Market Cap
- RVPH 18.1M
- IBIO 16.4M
- IPO Year
- RVPH N/A
- IBIO N/A
- Fundamental
- Price
- RVPH $0.54
- IBIO $1.14
- Analyst Decision
- RVPH Strong Buy
- IBIO Strong Buy
- Analyst Count
- RVPH 6
- IBIO 4
- Target Price
- RVPH $3.33
- IBIO $4.50
- AVG Volume (30 Days)
- RVPH 7.9M
- IBIO 8.6M
- Earning Date
- RVPH 11-13-2025
- IBIO 11-12-2025
- Dividend Yield
- RVPH N/A
- IBIO N/A
- EPS Growth
- RVPH N/A
- IBIO N/A
- EPS
- RVPH N/A
- IBIO N/A
- Revenue
- RVPH N/A
- IBIO $400,000.00
- Revenue This Year
- RVPH N/A
- IBIO N/A
- Revenue Next Year
- RVPH N/A
- IBIO $33.34
- P/E Ratio
- RVPH N/A
- IBIO N/A
- Revenue Growth
- RVPH N/A
- IBIO 77.78
- 52 Week Low
- RVPH $0.25
- IBIO $0.56
- 52 Week High
- RVPH $4.28
- IBIO $6.89
- Technical
- Relative Strength Index (RSI)
- RVPH 48.43
- IBIO 46.02
- Support Level
- RVPH $0.45
- IBIO $1.18
- Resistance Level
- RVPH $0.59
- IBIO $1.30
- Average True Range (ATR)
- RVPH 0.06
- IBIO 0.18
- MACD
- RVPH -0.01
- IBIO -0.05
- Stochastic Oscillator
- RVPH 41.93
- IBIO 5.00
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.